Effectiveness and Acceptability of Progestogens in Combined Oral Contraceptives - a Systematic Review

Overview

Journal Reprod Health

Publisher Biomed Central

Specialty Reproductive Medicine

Date 2004 Sep 11

PMID 15357865

Citations 8

Authors

Regina Kulier

Frans M Helmerhorst

Nandita Maitra

A Metin Gulmezoglu

Affiliations

Soon will be listed here.

Abstract

BACKGROUND: The progestogen component of oral contraceptives (OCs) has undergone changes since it was recognized that their chemical structure can influence the spectrum of minor adverse and beneficial effects. METHODS: The objective of this review was to evaluate currently available low-dose OCs containing ethinylestradiol and different progestogens in terms of contraceptive effectiveness, cycle control, side effects and continuation rates. The Cochrane Controlled Trials Register, MEDLINE and EMBASE databases were searched. Randomized trials reporting clinical outcomes were considered for inclusion and were assessed for methodological quality and validity. RESULTS: Twenty-two trials were included in the review. Eighteen were sponsored by pharmaceutical companies and in only 5 there was an attempt for blinding. Most comparisons between different interventions included one to three trials, involving usually less than 500 women. Discontinuation was less with second-generation progestogens compared to first-generation (RR 0.79; 95% CI 0.69-0.91). Cycle control appeared to be better with second-compared to first-generation progestogens for both, mono-and triphasic preparations (RR 0.69; 95% CI 0.52-0.91) and (RR 0.61; 95% CI 0.43-0.85), respectively. Intermenstrual bleeding was less with third- compared to second-generation pills (RR 0.71; 95% CI 0.55-0.91).Contraceptive effectiveness of gestodene (GSD) was comparable to that of levonorgestrel (LNG), and had similar pattern of spotting, breakthrough bleeding and absence of withdrawal bleeding). Drospirenone (DRSP) was similar compared to desogestrel (DSG) regarding contraceptive effectiveness, cycle control and side effects. CONCLUSION: The third- and second-generation progestogens are preferred over first generation in all indices of acceptability. Current evidence suggests that GSD is comparable to LNG in terms of contraceptive effectiveness and for most cycle control indices. GSD is also comparable to DSG. DRSP is comparable to DSG. Future research should focus on independently conducted well designed randomized trials comparing particularly the third- with second-generation progestogens.

Citing Articles

Strategies to safely target widely expressed soluble adenylyl cyclase for contraception.

Ferreira J, Levin L, Buck J Front Pharmacol. 2022; 13:953903.

PMID: 36091839 PMC: 9452739. DOI: 10.3389/fphar.2022.953903.

Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions.

Sekhon M, Cartwright M, Francis J BMC Health Serv Res. 2022; 22(1):279.

PMID: 35232455 PMC: 8887649. DOI: 10.1186/s12913-022-07577-3.

An intervention to improve the quality of life in children of parents with serious mental illness: the Young SMILES feasibility RCT.

Abel K, Bee P, Gega L, Gellatly J, Kolade A, Hunter D Health Technol Assess. 2020; 24(59):1-136.

PMID: 33196410 PMC: 7701992. DOI: 10.3310/hta24590.

Industry sponsorship and research outcome.

Lundh A, Lexchin J, Mintzes B, Schroll J, Bero L Cochrane Database Syst Rev. 2017; 2:MR000033.

PMID: 28207928 PMC: 8132492. DOI: 10.1002/14651858.MR000033.pub3.

Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework.

Sekhon M, Cartwright M, Francis J BMC Health Serv Res. 2017; 17(1):88.

PMID: 28126032 PMC: 5267473. DOI: 10.1186/s12913-017-2031-8.

References

Foidart J, Wuttke W, Bouw G, Gerlinger C, Heithecker R . A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000; 5(2):124-34. DOI: 10.1080/13625180008500387. View

Ramos R, APELO R, Osteria T, Vilar E . A comparative analysis of three different dose combinations of oral contraceptives. Contraception. 1989; 39(2):165-77. DOI: 10.1016/s0010-7824(89)80005-8. View

Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S . Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception. 1995; 51(4):225-9. DOI: 10.1016/0010-7824(95)00037-b. View

Singh M, Thomas D, Singh R, Saxena B, Ledger W . A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety. Eur J Contracept Reprod Health Care. 1996; 1(3):285-92. DOI: 10.3109/13625189609150671. View

Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T . Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception. 2000; 60(5):269-74. DOI: 10.1016/s0010-7824(99)00097-9. View

Serfaty D, Vree M . A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care. 1999; 3(4):179-89. DOI: 10.3109/13625189809167251. View

Dunson T, McLaurin V, Israngkura B, Leelapattana B, Mukherjee R, Perez-Palacios G . A comparative study of two low-dose combined oral contraceptives: results from a multicenter trial. Contraception. 1993; 48(2):109-19. DOI: 10.1016/0010-7824(93)90002-o. View

Halbe H, de Melo N, Bahamondes L, Petracco A, Lemgruber M, de Andrade R . Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care. 1998; 3(3):113-20. DOI: 10.3109/13625189809051413. View

Hillard P . Oral contraception noncompliance: the extent of the problem. Adv Contracept. 1992; 8 Suppl 1:13-20. DOI: 10.1007/BF01849447. View

10.

Huber J, Foidart J, Wuttke W, Merki-Feld G, The H, Gerlinger C . Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000; 5(1):25-34. DOI: 10.1080/13625180008500375. View

11.

Smith H, HUGHES G, DOUGLAS G, Hartley D, MCLOUGHLIN B, Siddall J . TOTALLY SYNTHETIC -13-ALKYL-3-HYDROXY AND METHOXY-GONA-1,3,5(10)-TRIEN-17-ONES AND RELATED COMPOUNDS. Experientia. 1963; 19:394-6. DOI: 10.1007/BF02171503. View

12.

Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W . Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. Contraception. 2001; 64(1):3-10. DOI: 10.1016/s0010-7824(01)00221-9. View

13.

Thorneycroft I . Cycle control with oral contraceptives: A review of the literature. Am J Obstet Gynecol. 1999; 180(2 Pt 2):280-7. DOI: 10.1016/s0002-9378(99)70719-2. View

14.

Droegemueller W, Katta L, Bright T, BOWES Jr W . Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol. 1989; 161(5):1407-11. DOI: 10.1016/0002-9378(89)90705-9. View

15.

Shoupe D . Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone. Obstet Gynecol. 1994; 83(5 Pt 1):679-85. View

16.

Reiter S, BAER L . Initial selection of oral contraceptives. J Reprod Med. 1990; 35(5):547-8. View

17.

Rossmanith W, Wirth U, Gasser S, Thun B, Steffens D . [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study]. Zentralbl Gynakol. 1997; 119(11):538-44. View

18.

ZICHELLA L, Sbrignadello C, Tomassini A, Di Lieto A, Montoneri C, Zarbo G . Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. Adv Contracept. 2000; 15(3):191-200. DOI: 10.1023/a:1006745315344. View

19.

Affinito P, Monterubbianesi M, Primizia M, Regine V, Di Carlo C, Farace M . Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecol Endocrinol. 1993; 7(4):259-66. DOI: 10.3109/09513599309152510. View

20.

Percival-Smith R, Yuzpe A, DESROSIERS J, Rioux J, Guilbert E . Cycle control on low-dose oral contraceptives: a comparative trial. Contraception. 1990; 42(3):253-62. DOI: 10.1016/0010-7824(90)90013-l. View